And for whatever reason, the FDA, despite approving a lot of kind of 'me too' type drugs, is not approved yet, but I think will shortly. That's when using an EGFR TKI in the adjuvant setting, that's probably the most practice-changing thing that's come out this year. You know, we can kind of go through some of them, as well as I don't know if you want to talk about the ADAURA trial, which hasn't been FDA approved, but likely will be soon. So, you know, some of them are a little head-scratching based on the standards that have been used in the past and some of them are, you know, the real deal we're quite excited about. It's unusual, and I'd say a fraction of them are actually practice changing. How surprising is it to see so many therapies in one disease state-approved in one month? Edj plans to make a few quiet, discrete inquiries to find out why.

“So, it's kind of a mixed bag.”ĬURE®: By all counts, the FDA approved seven therapies to treat non-small cell lung cancer back in May. But production of minzite, a mineral critical to anti-grav tech, has recently cratered. “Some of them are a little head scratching based on the standards that have been used in the past and some of them are, you know, the real deal we're quite excited about,” Burns, a medical oncologist at UPMC Hillman Cancer Center, said in a recent interview with CURE®. The recent surge of drug approvals in the non-small cell lung cancer (NSCLC) space by the Food and Drug Administration (FDA) is quite unusual - and only a fraction of them are considered practice-changing, according to Dr.

Outside of Space by Timothy Burns